Post-GSK Deal, Novartis is Shopping for Bolt-on Acquisitions

April 23, 2015

After concluding its $20 billion-plus three-part asset swap with GlaxoSmithKline, Novartis is reporting first quarter profits and back on the hunt for small acquisitions.

According to CEO Joe Jimenez, rather than looking for large transations, Novartis is looking for bolt-on acquisitions of $2 billion to $5 billion each.

According to the company, Novartis continues to stress a consistent focus on three core priorities – innovation, growth and productivity – when it comes to long-term strategy.

Read the Washington Post story